Efficacy News and Research

RSS

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

The antibodies are capable of neutralizing a wide range of SARS-CoV-2 variants even at sub-nanomolar concentrations. In addition, the combinations of these antibodies reduce the risk of generating escape mutants in vitro. The study is published in the journal Science.

5 Jul 2021

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

The findings reveal that the two-dose regimen of the vaccine is almost 90% effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Moreover, the vaccine shows high efficacy against the B.1.1.7 variant (Alpha) of SARS-CoV-2.

5 Jul 2021

Phylogenetic network analysis reveals recombinant origin of the SARS-CoV-2 alpha (B.1.1.7) variant

Researchers from the U.S. recently used the phylogenetic network approach to analyze the origin of the VOC202012/01 (alpha) or the PANGO Lineage B.1.1.7 variant, which was first reported in U.K. in 2020 and soon spread to other countries. This study is published on the bioRxiv preprint server while the paper undergoes peer review.

5 Jul 2021

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

Researchers in the Netherlands have conducted a study showing that Janssen’s Ad26.COV2.S coronavirus disease 2019 (COVID‐19) vaccine was effective against variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among eight individuals.

4 Jul 2021

COVID-19 vaccination induces highly variable immunity among the immunocompromised

Researchers in the United States have conducted a study showing that the humoral (antibody) immunity induced by vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – varies significantly among immunocompromised individuals.

4 Jul 2021

Researchers repurpose existing drugs to reduce severity of sleep apnea by at least 30%

New research published in The Journal of Physiology shows that researchers have successfully repurposed two existing medications to reduce the severity of sleep apnea in people by at least 30 per cent.

2 Jul 2021

Study demonstrates successful postinfection treatment for SARS-CoV-2

A recent study by Kansas State University virologists demonstrates successful postinfection treatment for SARS-CoV-2, the virus that causes COVID-19.

2 Jul 2021

Repurposing existing medications to reduce the severity of sleep apnea

In an Australian world-first, researchers have successfully repurposed two existing medications to reduce the severity of sleep apnea in people by at least 30 per cent.

2 Jul 2021

Curtin researchers awarded almost $500,000 funding to help improve care for TBI patients

Curtin University researchers have been awarded almost $500,000 in Federal Government funding to help improve care for people with traumatic brain injury (TBI), including those in rural, remote and Aboriginal communities.

2 Jul 2021

Stool transplant may be worth exploring as treatment option for COVID-19

It might be worth exploring stool transplant to treat COVID-19 infection, suggest doctors in a letter published online in the journal Gut, after they used the procedure in two patients to prevent the recurrence of another bacterial infection.

2 Jul 2021

New PET imaging method tracks immunotherapeutic efficacy in mouse models

Several cancer tumors grow through immunosuppression; that is, they manipulate biological systems in their microenvironments and signal to a specific set of immune cells--those that clear out aberrant cells--to stop acting. It is no wonder that immunotherapy designed to re-establish anti-tumor immunity is rapidly becoming the treatment of choice for these cancers.

2 Jul 2021

Mutations in the spike proteins of SARS-CoV-2 select for amino acid changes, increasing protein stability

A team of researchers recently demonstrated that mutations in the S protein of SARS-CoV-2 select for amino acid changes that result in a more stable protein than would otherwise be expected.

1 Jul 2021

Mustard seed, wall rocket and turmeric extracts show potential against SARS-CoV-2 in vitro

Researchers in Spain have identified plant extracts that may be of interest in the search for treatments of coronavirus disease 2019 (COVID-19) and serve as a basis for future chemical, in vivo, and clinical trials.

1 Jul 2021

Anti-malarial drug shows promise in the battle against COVID-19

In the "war" that the world has been fighting against COVID-19, scientists have been scanning their arsenals of previously used drugs in hopes of finding any that can be used to treat the disease.

1 Jul 2021

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

In a recently published article scientists have provided a detailed description of the utility of mannose-specific lectins in preventing coronavirus infections. They have specifically explained how mannose-specific lectins derived from plants, algae, fungi, and bacteria selectively bind N-glycans present on the surface of viral spike protein and how such interactions can be medically utilized to control coronavirus transmission.

1 Jul 2021

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

A recent Diagnostics study discusses the specific antibody response that occurred in individuals after they had received the SARS-CoV-2 vaccine.

1 Jul 2021

Can age, sex, BMI or blood group influence the immunogenicity of the Pfizer/BioNTech COVID-19 vaccine?

A group of Belgium researchers recently discuss their findings in the journal Microorganisms, which describe the influence of several factors on vaccine-induced immunogenicity.

1 Jul 2021

New malaria vaccine is undergoing Phase 1 trials but current results show it provides strong and long-lasting protection

A new malaria vaccine could be the breakthrough in developing an effective and lasting treatment.

1 Jul 2021

Individuals who contract COVID-19 after vaccination are likely to have a lower viral load

Individuals who contract COVID-19 even after vaccination are likely to have a lower viral load, experience a shorter infection time and have milder symptoms than people who are unvaccinated, according to research that includes data from ongoing University of Arizona Health Sciences studies.

1 Jul 2021

COVID mRNA vaccines induce antibodies against three SARS-CoV-2 variants

Researchers at the Institute of Biomedicine, the University of Turku in Finland showed that the blood of BNT162b2-vaccinated health care workers effectively neutralized the SARS-CoV-2 variant with the D614G substitution and the B.1.1.7 variant (Alpha variant) after the second dose.

1 Jul 2021

Efficacy News and Research

Scientists identify natural SARS-CoV-2 super immunity against 23 variants

Novavax COVID-19 vaccine demonstrates ~90% efficacy against SARS-CoV-2

Phylogenetic network analysis reveals recombinant origin of the SARS-CoV-2 alpha (B.1.1.7) variant

Janssens’ COVID-19 vaccine effective against SARS-CoV-2 Delta variant

COVID-19 vaccination induces highly variable immunity among the immunocompromised

Researchers repurpose existing drugs to reduce severity of sleep apnea by at least 30%

Study demonstrates successful postinfection treatment for SARS-CoV-2

Repurposing existing medications to reduce the severity of sleep apnea

Curtin researchers awarded almost $500,000 funding to help improve care for TBI patients

Stool transplant may be worth exploring as treatment option for COVID-19

New PET imaging method tracks immunotherapeutic efficacy in mouse models

Mutations in the spike proteins of SARS-CoV-2 select for amino acid changes, increasing protein stability

Mustard seed, wall rocket and turmeric extracts show potential against SARS-CoV-2 in vitro

Anti-malarial drug shows promise in the battle against COVID-19

Study explores lectins from plants, fungi, algae and cyanobacteria as pan-coronavirus inhibitors

Study evaluates neutralizing antibody responses elicited by the Pfizer/BioNTech COVID-19 vaccine

Can age, sex, BMI or blood group influence the immunogenicity of the Pfizer/BioNTech COVID-19 vaccine?

New malaria vaccine is undergoing Phase 1 trials but current results show it provides strong and long-lasting protection

Individuals who contract COVID-19 after vaccination are likely to have a lower viral load

COVID mRNA vaccines induce antibodies against three SARS-CoV-2 variants

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News